20% Returns in 1 Month: This Piramal Group Pharma Stock Reports 17% Revenue Growth in Q1FY26; Will the Rally Continue Towards Its All-Time High?
Join Us
Follow Us
Piramal Pharma reported healthy Q1 FY27 growth across all three business segments, with strong EBITDA expansion driven by improved operating leverage, higher capacity utilisation and robust execution
✨ Key Takeaways
On Thursday, Indian equity benchmark indices traded marginally higher, with the benchmark Nifty 50 index rising 4.30 points, or 0.02 per cent, to 24,254.50. Amid the positive market sentiment, Piramal Pharma share price gained 0.90 per cent to Rs 197.45. The stock has rallied around 20 per cent over the past one month, supported by strong Q1 FY27 earnings, raising investor interest over whether the momentum could continue towards its all-time high.
Piramal Pharma Q1 FY27 Results
Piramal Pharma reported a healthy financial performance for the quarter ended June 30, 2026. Consolidated revenue from operations increased 17 per cent YoY to Rs 2,270 crore from Rs 1,934 crore in the corresponding quarter last year. Total income also rose 18 per cent YoY to Rs 2,359 crore.
Searching for the Next Multibagger Opportunity?
Explore DSIJ’s Multibagger Pick - a research-driven service focused on identifying fundamentally strong companies with the potential to generate exceptional long-term returns.
Download Service BrochureEBITDA registered strong growth of 72 per cent YoY to Rs 285 crore from Rs 165 crore, while EBITDA margin expanded by around 400 basis points to 12.5 per cent from 8.5 per cent in Q1 FY26. Net loss before exceptional items narrowed to Rs 69 crore from Rs 102 crore, while net loss after exceptional items improved to Rs 69 crore compared with Rs 82 crore in the year-ago quarter.
Also Read - Waaree Energies Share Price Falls 5% Despite Total Revenue Crossing Rs 8,100 Crore; Here's Why
Segment Performance
The company's CDMO business delivered revenue of Rs 1,187 crore, registering 19 per cent YoY growth, supported by healthy order inflows, improved request-for-proposal (RFP) activity, enhanced commercial capabilities and strong execution across its global manufacturing network. The company also maintained its Zero Official Action Indicated (OAI) quality record after its Sellersville facility in the US received an Establishment Inspection Report from the US FDA.
The Complex Hospital Generics (CHG) business reported revenue of Rs 743 crore, up 17 per cent YoY. The company retained its leadership in the US Sevoflurane market with a 48 per cent value share, maintained the number one position in the US intrathecal Baclofen market and expects supplies of Kenalog to begin from Q2 FY27.
The Consumer Healthcare (PCH) business posted revenue of Rs 347 crore, up 15 per cent YoY. Power Brands grew 23 per cent, contributing 53 per cent of consumer healthcare sales, while the e-commerce business expanded 40 per cent YoY, accounting for 28 per cent of sales. The company also continued to invest around 12 per cent of PCH sales towards media and brand promotion while expanding its distribution network.
About Piramal Pharma
Piramal Pharma Ltd is a global pharmaceutical company operating through three business segments: Piramal Pharma Solutions (CDMO), Piramal Critical Care (Complex Hospital Generics) and Piramal Consumer Healthcare. The company has 17 global development and manufacturing facilities and a distribution network spanning more than 100 countries, serving customers across pharmaceuticals, healthcare and wellness products.
Add DSIJ as your preferred news source on G o o g l e
Add NowDo you think Piramal Pharma's strong Q1 FY27 performance and recent 20% rally can help the stock move towards its all-time high? Share your views in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.